X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2026)
X4 Pharmaceuticals' EBITDA Margin was -174.81% in Q2 2026, up 1136.74 percentage points from -1311.56% a year earlier and up 566.80 percentage points from the prior quarter.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) EBITDA Margin (2018 - 2026) Analysis & Trends
On a trailing twelve-month basis, X4 Pharmaceuticals' EBITDA Margin was -544.20% through Jun 30, 2026, down 225.29 percentage points year-over-year; for FY2025, it came in at -243.80%, up 1148.65 percentage points from FY2024.
- EBITDA Margin shows a five-year change of +1740.30 percentage points (FY2020 to FY2025).
- In earlier years, EBITDA Margin was -1392.45% in FY2024.
- The Q2 2026 figure marks the highest quarterly EBITDA Margin since Q1 2025.
- Compared with a year earlier, EBITDA Margin was higher in three of the last five quarters, with an average year-over-year change of -1484.92 percentage points.
- Per Business Quant data, XFOR's EBITDA Margin in the three quarters before Q2 2026 was -741.62% (Q1 2026), -914.17% (Q4 2025) and -1545.95% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | X4 Pharmaceuticals | 381.56 Mn | -317.13 Mn | 7.19 Mn | -174.81% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -174.81% |
| Mar 31, 2026 | -741.62% |
| Dec 31, 2025 | -914.17% |
| Sep 30, 2025 | -1,545.95% |
| Jun 30, 2025 | -1,311.56% |
| Mar 31, 2025 | -31.13% |
| Dec 31, 2024 | -2,471.55% |
| Sep 30, 2024 | -6,113.04% |
| Jun 30, 2024 | 12,663.77% |
| Mar 31, 2020 | -351.50% |
| Dec 31, 2018 | -229.37% |
API Access
X4 Pharmaceuticals EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=XFOR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "XFOR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=XFOR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();